Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.
about
Current status of immunotherapyExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyConcepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesModulation of APC Function and Anti-Tumor Immunity by Anti-Cancer DrugsTrial Watch: Adoptive cell transfer for oncological indicationsRelevance of tumor-infiltrating lymphocytes in breast cancerMyeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor MicroenvironmentThe interaction of anticancer therapies with tumor-associated macrophagesTargeting Immune Regulatory Networks to Counteract Immune Suppression in CancerImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationInterplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend?Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model.Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axisAccumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancerIL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsHuman papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 level in patients with colorectal cancer.Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes.Enhancement of T cell recruitment and infiltration into tumours.Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignanciesEx vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure.Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy.Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 expression in patients with breast cancerTumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailtyRPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
P2860
Q26773314-E1EDBF9C-65F6-4992-8C10-B562003DB074Q26779184-4A36406F-91CA-4357-92FA-10774155F411Q26781215-8591E0F4-0BCA-4E04-9767-1BA81577AECDQ26781522-AA59E8F6-B154-45B9-921D-AB33A52F7A9FQ26785545-D31C1B47-8CBC-481A-B131-073A78B38B55Q26795598-2D0DD9B7-B215-45F6-8287-2C54D8C18983Q26799126-49EA235A-D8A6-49B2-B327-E00F7AB71525Q27016634-6DFD407A-EE72-4A20-9883-2B8118FA68D7Q28066486-28FCEC57-4B9B-4AFB-B30A-9046A2FEBE55Q28068378-AA199E83-2593-42E8-BB5E-5CA995EEA9DFQ28070110-996A518A-349A-443E-85A7-0ED9D7B07D5BQ33554629-C64ECC4D-C5F5-4CE9-8B5E-9F5FDC65680CQ33563230-F85016BB-7F95-4246-B573-01D46333B84AQ33641799-8E6993B7-6D35-4AEC-BCA3-1F541CA6BEA2Q33660069-34D65A76-CD05-4995-B0E2-66B89A2AC48AQ33778945-833BA477-329E-4F1B-B64F-DFBDA217B216Q33838944-D2343AB5-51E3-4B3A-A7B8-B29EEBCB159EQ33888808-93A93B83-C49A-4DCD-9332-2C6BF27DB929Q34483744-B447AA23-F96E-433F-A6A0-9E712AA0A6F2Q35071850-3CC59258-8B29-445B-9A14-F44A912A0EFFQ35112546-C823B65F-0238-415B-87F2-AE49FCA3A96EQ35149189-52CB44D3-68CC-4161-B202-E5F00B9DE6FEQ35178939-DBE48E4E-5582-41A9-9D73-683A54340EC5Q35506459-7E8F9AA4-D160-45C8-9271-E640FD529EC8Q35506659-947BBC19-BF04-4110-B10F-FCDEC4244E3FQ35538728-997EBBD3-D327-4C25-A08F-41070241FF68Q35828574-7AB4276C-8F53-4756-9644-5C968D4B6DBDQ35863346-1E5B10A0-4736-4ACF-ACC3-98C1B713E682Q36224057-05C5C4D8-A218-47B3-A5DD-B22E6BD0D451Q36688932-65042085-F421-4B4D-9E9B-5A62FD4F6D19Q36781992-C9DC7E63-6C1A-4623-92DD-2EDA32293442Q36796146-29F0C7AD-02A4-4A93-8F1F-0983C736FCF1Q37144134-BD56D83F-0AD9-4732-B5E5-E9FCC0C6ACF9Q37160109-D83949A2-AA15-4990-9178-F3A3558FE44DQ37316603-5C10D82D-F2E2-4C53-B7F6-21C9F3ECA4DBQ37317367-2680C7AD-2FAC-4E58-BDF9-F4586317E27BQ37544847-A7EC8B88-3910-41AB-BE48-50E56151BF8FQ37665711-FE24C90D-4064-43D5-9036-1BC8DC25D229Q37671301-508B7882-ADDD-49D1-A8EF-08A72B67D46CQ37684367-945B3388-C716-4902-B098-C32993246DD1
P2860
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Doxorubicin eliminates myeloid ...... ell transfer in breast cancer.
@en
Doxorubicin eliminates myeloid ...... ell transfer in breast cancer.
@nl
type
label
Doxorubicin eliminates myeloid ...... ell transfer in breast cancer.
@en
Doxorubicin eliminates myeloid ...... ell transfer in breast cancer.
@nl
prefLabel
Doxorubicin eliminates myeloid ...... ell transfer in breast cancer.
@en
Doxorubicin eliminates myeloid ...... ell transfer in breast cancer.
@nl
P2093
P2860
P1433
P1476
Doxorubicin eliminates myeloid ...... cell transfer in breast cancer
@en
P2093
Claire B Larmonier
Darya Alizadeh
Emmanuel Katsanis
Malika Trad
Neale T Hanke
Nicolas Larmonier
Nona Janikashvili
P2860
P304
P356
10.1158/0008-5472.CAN-13-1545
P407
P577
2013-11-06T00:00:00Z